Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications

Abstract

Metabolic alterations could profoundly affect immune functions and influence the progression and outcome of autoimmune diseases. However, the detailed mechanisms and their therapeutic potential remain to be defined. Here, we show that phosphatidylinositide 3-kinase interacting protein 1 (Pik3ip1), a newly identified negative immune regulator, is notably down-regulated in several major autoimmune diseases through a previously unidentified mechanism mediated by interleukin-21/p38 mitogen-activated protein kinase/a disintegrin and metalloprotease-17 (ADAM17) pathway. Down-regulation of Pik3ip1 in T cells causes a major metabolic shift from oxidative phosphorylation toward aerobic glycolysis, leading to their overactivation and aggressive disease progression in experimental autoimmune encephalomyelitis (EAE) mouse model. Suppression of hypoxia-inducible factor 1α (Hif1α) or pharmacologic inhibition of glycolysis could reverse these phenotypes and largely mitigate EAE severity. Our study reveals a previously unrecognized role of Pik3ip1 in metabolic regulation that substantially affects the inflammatory loop in the autoimmune setting and identifies the Pik3ip1/Hif1α/glycolysis axis as a potential therapeutic target for treatment of autoimmune diseases.

CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1

“…PIK3IP1 is a recently discovered negative regulator of PI3K, which can bind p110 and prevent its activation by p85, thereby down-regulating PI3K signaling to inhibit tumor growth [ 36 , 37 ]. Recent studies suggest that PIK3IP1 may act as a tumor suppressor to regulate tumor cell function [ 37 ] and anti-tumor immune activity [ 38 , 39 ]. In addition, PIK3IP1 is highly expressed in PI3Kα inhibitor-sensitive gastric cancer cells and can be used as a marker to detect the anti-cancer activity of PI3Kα inhibitor [ 40 ].…”

Screening for immune-related biomarkers associated with myasthenia gravis and dilated cardiomyopathy based on bioinformatics analysis and machine learning

“…In the field of autoimmune diseases, PIK3IP1 is considered a key regulatory factor. This signaling plays a crucial role in the activation and regulation of immune cells, directly impacting their proliferation, differentiation, and activation state [ 23 ]. Research has also shown that by modulating the activity of the PI3K signaling pathway, PIK3IP1 affects biological processes such as proliferation, survival, and apoptosis in myocardial cells.…”

Identification of potential immunologic resilience in the healing process of diabetic foot ulcers

“… 44 PIK3IP1 is an upstream inhibitor of phosphoinositide 3‐kinase (PI3K) signalling, a novel negative immune regulatory factor. 45 These genes may play a significant role in the development and treatment of DFU.…”

“…TSC22D3 is a well‐known glucocorticoid‐induced gene with anti‐inflammatory effects and is also involved in regulating the differentiation of helper T cells 44 . PIK3IP1 is an upstream inhibitor of phosphoinositide 3‐kinase (PI3K) signalling, a novel negative immune regulatory factor 45 . These genes may play a significant role in the development and treatment of DFU.…”